Full access
Clinical & Research News
Published Online: 7 January 2005

Strattera Gets Stronger Label Warning

Jim RosackAuthors Info & Affiliations
Publication: Psychiatric News
Volume 40, Number 1
https://doi.org/10.1176/pn.40.1.00400026a
Prompted by two reports of severe liver injury among the more than 2 million patients who have taken atomoxetine (Strattera) for attention-deficit/hyperactivity disorder (ADHD), Eli Lilly and Co., in cooperation with the U.S. Food and Drug Administration (FDA), will add a bolded warning to the drug's label immediately.
“Patient safety is our top priority at Lilly,” said Douglas Kelsey, M.D., a clinical research physician at Lilly and a pediatrician, in a prepared statement. “When we learned of the first case, we reported it to the FDA and began a thorough investigation, including consultation with outside experts and a review of all available data.”
The company worked closely with the FDA to determine what action to take. Lilly will notify health care professionals in a “Dear Doctor” letter. Patients will be informed that they should contact their doctor immediately if they develop pruritus, jaundice, darkened urine, upper-right-sided abdominal pain or tenderness, or any unexplained“ flu-like” symptoms.
The company's review concluded that “the clinical trial and real-world data indicate that the benefit-risk profile for Strattera is positive, and the medication continues to be an important treatment option for patients with ADHD.”
In more than 6,000 patients taking atomoxetine during clinical trials, no cases of liver injury were noted. Lilly's statement stresses that although only two postmarketing cases have been reported, “because of probable underreporting, it is impossible to provide an accurate estimate of the true incidence of these events.”
The statement goes on to say that “even when accounting for underreporting, real-world incidence of liver injury among patients taking the medication is less than the rate expected for the overall population.”
More information is available by calling the Lilly Answers Center at (800) or LillyRx at (800) 545-5979 or online at<www.strattera.com>.▪

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 40 • Number 1 • January 7, 2005
Pages: 26

History

Published online: 7 January 2005
Published in print: January 7, 2005

Authors

Affiliations

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share